Submission involving Lymph Node Metastasis within Esophageal Squamous Mobile or portable Carcinoma Right after Trimodal Treatment: Revision history

Jump to: navigation, search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 January 2024

  • curprev 11:2011:20, 16 January 2024‎ Trunkplanet3 talk contribs‎ 3,542 bytes +3,542‎ Created page with "Cabozantinib confirmed a favorable benefit-risk user profile within Japan sufferers together with advanced hepatocellular carcinoma (HCC) within an open-label, period II examine (NCT03586973). This analysis provides snowballing data in order to last databases lock. Sufferers with formerly taken care of, superior HCC gotten cabozantinib 60mg/day. Progression-free survival (PFS) and tumour reply rates inside prior-sorafenib and sorafenib-naïve cohorts ended up evaluated s..."
Retrieved from "https://news.npo.digital/index.php?title=Submission_involving_Lymph_Node_Metastasis_within_Esophageal_Squamous_Mobile_or_portable_Carcinoma_Right_after_Trimodal_Treatment"